GOLDENWELL BIOTECH Restates Q2 2025 Financials, Discloses Going Concern and Ineffective Controls

summarizeSummary

GOLDENWELL BIOTECH filed an amended quarterly report, restating its Q2 2025 financials due to errors in revenue recognition and expense timing, which increased its net loss and accumulated deficit. The company also disclosed a going concern warning and ineffective disclosure controls.

check_boxKey Events · Corporate Governance and Compliance · GWLL

• Financial Restatement Confirmed

  Restated Q2 2025 financials due to errors in revenue recognition and expense timing, increasing the net loss from $(5,220) to $(28,900) and the accumulated deficit by $29,241. This follows the May 27, 2026 8-K advising non-reliance on previous financials.

• Going Concern Warning

  Management explicitly stated substantial doubt about the company's ability to continue as a going concern due to recurring losses and dependence on future capital raises, with an accumulated net loss of $1,428,481 since inception.

• Ineffective Disclosure Controls

  Management concluded that disclosure controls and procedures were not effective as of March 31, 2025, indicating material weaknesses in financial reporting.

auto_awesomeAnalysis · GWLL · Manufacturing

This filing provides the restated financial statements for Q2 2025, confirming the issues previously disclosed in the May 27, 2026 8-K regarding non-reliance on prior financials. The restatement significantly increased the net loss and accumulated deficit, highlighting severe financial reporting errors. The company explicitly states substantial doubt about its ability to continue as a going concern and reported ineffective disclosure controls, indicating fundamental operational and financial instability.